Filtered By:
Drug: Zetia
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 236 results found since Jan 2013.
Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Curr Vasc Pharmacol. 2021 Nov 9. doi: 10.2174/1570161119666211109122231. Online ahead of print.ABSTRACTStroke is the second most common cause of death worldwide. The rates of stroke are increasing in less affluent countries predominantly because of a high prevalence of modifiable risk factors. The Lipid Association of India (LAI) has provided a risk stratification algorithm for patients with ischaemic stroke and recommended low density lipoprotein cholesterol (LDL-C) goals for those in a very high risk group and extreme risk group (category A) of <50 mg/dl (1.3 mmol/l) while the LDL-C goal for extreme risk group (catego...
Source: Current Vascular Pharmacology - November 9, 2021 Category: Drugs & Pharmacology Authors: Raman Puri Vimal Mehta S S Iyengar Padma Srivastava Jamal Yusuf Akshaya Pradhan Jeyaraj Durai Pandian Vijay K Sharma P N Renjen A Muruganathan K Mugundhan A V Srinivasan Sadanand Shetty S N Narasingan Devaki R Nair Manish Bansal D Prabhakar Mukul Varma Vi Source Type: research
Intracranial Hemorrhage in the TST Trial
CONCLUSIONS: Targeting an LDL cholesterol of <70 mg/dL compared with 100±10 mg/dL in patients with atherosclerotic ischemic stroke nonsignificantly increased the risk of ICH. Incident ICHs were not associated with low LDL cholesterol. Uncontrolled hypertension and anticoagulant therapy were associated with ICH which has important clinical implications.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01252875; EUDRACT identifier: 2009-A01280-57.PMID:34963300 | DOI:10.1161/STROKEAHA.121.035846
Source: Atherosclerosis - December 29, 2021 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Philippa C Lavall ée Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.
CONCLUSIONS: High potency lipid-lowering therapy effectively reduces the risk of recurrent IS in diabetic patients regardless of ATOR or EZ-SIM combination therapy.
PMID: 27270238 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - June 5, 2016 Category: Endocrinology Authors: Liu CH, Chen TH, Lin MS, Hung MJ, Chung CM, Cherng WJ, Lee TH, Lin YS Tags: J Clin Endocrinol Metab Source Type: research
Optimization of secondary prevention in patients with high-risk atherothrombotic ischemic stroke or transient ischemic attacks
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(6):36-43. doi: 10.17116/jnevro202312306136.ABSTRACTHigh and very high risk atherothrombotic ischemic stroke (ATIS) includes patients with severe extracranial atherosclerosis, any intracranial atherosclerosis, and aortic arch atheromatosis. The article discusses the most effective approaches to medical short- and long-term secondary prevention of ATIS, major vascular events and death, based on the results of modern research and current clinical guidelines. Clinical studies of recent years have proven the possibility of individualization and intensification of secondary preventi...
Source: Atherosclerosis - June 29, 2023 Category: Cardiology Authors: A A Kulesh S N Yanishevskiy D A Demin L I Syromyatnikova O I Vinogradov Source Type: research
Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease
Abstract
After careful review of randomized cardiovascular outcomes trial data, the 2013 ACC/AHA cholesterol guideline focused on using the appropriate intensity of statin therapy to reduce atherosclerotic cardiovascular disease (ASCVD) risk and moved away from recommending specific low-density lipoprotein cholesterol (LDL-C) treatment targets. In patients who have had a stroke or other clinical ASCVD event, a high-intensity statin should be initiated up to age 75 years unless there are safety concerns, including a history of hemorrhagic stroke. A moderate-intensity statin is recommended if there are safety conc...
Source: Current Neurology and Neuroscience Reports - February 2, 2016 Category: Neuroscience Source Type: research
Ezetimibe With Statin Therapy for Stroke Prevention in ACS Ezetimibe With Statin Therapy for Stroke Prevention in ACS
Can the addition of ezetimibe to simvastatin in patients stabilized after acute coronary syndrome reduce the frequency of ischemic stroke?Circulation
Source: Medscape Today Headlines - January 30, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia.
Abstract
Statins, 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors, have been used for decades for the prevention of coronary artery disease and stroke. They act primarily by lowering serum cholesterol through the inhibition of cholesterol synthesis in the liver, which results in the upregulation of low-density lipoprotein receptors in the liver. This results in the removal of low-density lipoprotein-cholesterol. Studies have suggested that statins may demonstrate additional effects that are independent of their effects on low-density lipoprotein-cholesterol. These have been termed "pleiotropic" effects. P...
Source: Current Vascular Pharmacology - August 17, 2018 Category: Drugs & Pharmacology Authors: Liao JK, Oesterle A Tags: Curr Vasc Pharmacol Source Type: research
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891625 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E Tags: Circulation Source Type: research
Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891624 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Koh KK Tags: Circulation Source Type: research
Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891623 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Cordero A, Bertomeu-González V, Rodriguez-Mañero M Tags: Circulation Source Type: research
Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891622 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Thomopoulos C, Michalopoulou H Tags: Circulation Source Type: research
Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891621 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Del Pinto R, Ferri C, Borghi C Tags: Circulation Source Type: research
Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Proprotein convertase subtilisin/kexin type 9 (PCSK9) interacts with the low-density lipoprotein (LDL) receptor and, by enhancing its degradation, has a pivotal role in the regulation of cholesterol homeostasis. Two fully humanized monoclonal antibodies targeting PCSK9, evolocumab and alirocumab, are available for clinical use. PCSK9 inhibitors reduce LDL-C 30% more than ezetimibe and 60% more than placebo when added to statins. This reduction in LDL-C is accompanied by a decrease in the risk of major cardiovascular and cerebrovascular events.
Source: Journal of Stroke and Cerebrovascular Diseases - August 24, 2021 Category: Neurology Authors: Bayan Moustafa, Fernando D Testai Tags: Review Article Source Type: research
